An enhanced prophylactic regimen using widely available and easy-to-use agents significantly reduced the incidence and severity of dermatologic reactions associated with first-line amivantamab plus lazertinib in epidermal growth factor receptor (EGFR)-mutant advanced non–small cell lung cancer (NSCLC), early data from the COCOON trial showed. Compared with standard-of-care dermatologic management, the enhanced prophylactic skin regimen led […]
The post Skin Care Regimen Cuts Toxicities of Combo NSCLC Therapy first appeared on News Health.
Author : News Health
Publish date : 2025-04-01 08:39:00
Copyright for syndicated content belongs to the linked Source.